Arvinas (NASDAQ:ARVN – Get Free Report) posted its quarterly earnings results on Tuesday. The company reported ($0.63) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.07) by $0.44, Zacks reports. During the same period in the prior year, the firm posted ($2.53) earnings per share.
Arvinas Stock Up 1.5 %
ARVN stock opened at $17.95 on Thursday. Arvinas has a fifty-two week low of $16.61 and a fifty-two week high of $53.08. The business has a 50-day moving average of $19.18 and a 200-day moving average of $23.32.
Wall Street Analysts Forecast Growth
A number of research firms have issued reports on ARVN. BTIG Research initiated coverage on shares of Arvinas in a research report on Tuesday, December 10th. They set a “buy” rating and a $69.00 target price on the stock. Guggenheim restated a “buy” rating and issued a $57.00 price objective on shares of Arvinas in a report on Wednesday. HC Wainwright reaffirmed a “buy” rating and set a $87.00 target price on shares of Arvinas in a report on Wednesday, December 11th. Barclays cut their price target on Arvinas from $48.00 to $32.00 and set an “overweight” rating on the stock in a research note on Monday, February 3rd. Finally, BMO Capital Markets reaffirmed an “outperform” rating and set a $82.00 price objective (down from $88.00) on shares of Arvinas in a research note on Wednesday. One equities research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $59.58.
Arvinas Company Profile
Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.
Featured Stories
- Five stocks we like better than Arvinas
- The Role Economic Reports Play in a Successful Investment Strategy
- Lattice Semiconductor’s Market Reset Is Over: The Rebound Begins
- Most Volatile Stocks, What Investors Need to Know
- Will Eli Lilly Stock Keep Climbing? Q2 Trial Results Are Crucial
- What Are Growth Stocks and Investing in Them
- Double-Digit Gains Ahead? These 2 Cybersecurity Stocks Look Ready
Receive News & Ratings for Arvinas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arvinas and related companies with MarketBeat.com's FREE daily email newsletter.
